Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
BackgroundAnti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of patients. ICI-treated patients develop unique toxicities - immune related adverse events (irAEs) – that arise from unrestrained immune ac...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bb1201d2dc294e4d8fa1c2c7bb33a26c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:bb1201d2dc294e4d8fa1c2c7bb33a26c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:bb1201d2dc294e4d8fa1c2c7bb33a26c2021-12-01T08:02:17ZImmune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis2234-943X10.3389/fonc.2021.749064https://doaj.org/article/bb1201d2dc294e4d8fa1c2c7bb33a26c2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.749064/fullhttps://doaj.org/toc/2234-943XBackgroundAnti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of patients. ICI-treated patients develop unique toxicities - immune related adverse events (irAEs) – that arise from unrestrained immune activation. The link between irAE development and clinical outcome in melanoma and other cancers is inconsistent; and little data exists on the occurrence of multiple irAEs. We sought to characterize development of single and multiple irAEs, and association of irAE(s) development with clinical variables and impact upon outcomes in advanced melanoma patients treated with anti-PD-1 ICIs.MethodsWe conducted a retrospective study of 190 patients with metastatic melanoma treated with single-agent anti-PD-1 ICI therapy between June 2014 and August 2020 at a large integrated network cancer center identified through retrospective review of pharmacy records. irAEs were graded based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Results190 patients were evaluated of whom 114 patients (60.0%) experienced ≥1 irAE, including 30 (15.8%) with grade 3/4 irAEs. The occurrence of any irAE was strongly associated with the development of investigator-assessed response to anti-PD-1 therapy (p < 0.0001); whether evaluated by current (p=0.0082) or best (p=0.0001) response. In patients with ≥2 irAEs, distinct patterns were observed. Median progression-free survival (PFS) and overall survival (OS) were greater in those with any irAE compared to those without (PFS, 28 months vs. 5 months, p < 0.0001; OS, not reached vs. 9 months, p < 0.0001). Development of ≥2 irAEs had a trend towards improved PFS and OS compared to those who developed a single irAE, although this did not reach statistical significance (p=0.2555, PFS; p=0.0583, OS). Obesity but not age or gender was distinctly associated with irAE development.ConclusionsIn this study, we demonstrated that irAE occurrence was significantly associated with response to anti-PD-1 therapy and improved PFS/OS. Those who developed multiple irAEs had a trend towards improved PFS and OS compared to those who developed only a single irAE. Increased BMI but neither age nor gender were associated with irAE development. Distinct patterns of irAEs observed suggest shared etiopathogenetic mechanisms.Melissa L. BastackyHong WangDylan FortmanZahra RahmanGerard P. MascaraTimothy BrennerYana G. NajjarYana G. NajjarJason J. LukeJason J. LukeJohn M. KirkwoodJohn M. KirkwoodHassane M. ZarourHassane M. ZarourDiwakar DavarDiwakar DavarFrontiers Media S.A.articlemelanomametastaticimmunotherapyCTLA-4PD-1immune related adverse eventsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
melanoma metastatic immunotherapy CTLA-4 PD-1 immune related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
melanoma metastatic immunotherapy CTLA-4 PD-1 immune related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Melissa L. Bastacky Hong Wang Dylan Fortman Zahra Rahman Gerard P. Mascara Timothy Brenner Yana G. Najjar Yana G. Najjar Jason J. Luke Jason J. Luke John M. Kirkwood John M. Kirkwood Hassane M. Zarour Hassane M. Zarour Diwakar Davar Diwakar Davar Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis |
| description |
BackgroundAnti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of patients. ICI-treated patients develop unique toxicities - immune related adverse events (irAEs) – that arise from unrestrained immune activation. The link between irAE development and clinical outcome in melanoma and other cancers is inconsistent; and little data exists on the occurrence of multiple irAEs. We sought to characterize development of single and multiple irAEs, and association of irAE(s) development with clinical variables and impact upon outcomes in advanced melanoma patients treated with anti-PD-1 ICIs.MethodsWe conducted a retrospective study of 190 patients with metastatic melanoma treated with single-agent anti-PD-1 ICI therapy between June 2014 and August 2020 at a large integrated network cancer center identified through retrospective review of pharmacy records. irAEs were graded based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Results190 patients were evaluated of whom 114 patients (60.0%) experienced ≥1 irAE, including 30 (15.8%) with grade 3/4 irAEs. The occurrence of any irAE was strongly associated with the development of investigator-assessed response to anti-PD-1 therapy (p < 0.0001); whether evaluated by current (p=0.0082) or best (p=0.0001) response. In patients with ≥2 irAEs, distinct patterns were observed. Median progression-free survival (PFS) and overall survival (OS) were greater in those with any irAE compared to those without (PFS, 28 months vs. 5 months, p < 0.0001; OS, not reached vs. 9 months, p < 0.0001). Development of ≥2 irAEs had a trend towards improved PFS and OS compared to those who developed a single irAE, although this did not reach statistical significance (p=0.2555, PFS; p=0.0583, OS). Obesity but not age or gender was distinctly associated with irAE development.ConclusionsIn this study, we demonstrated that irAE occurrence was significantly associated with response to anti-PD-1 therapy and improved PFS/OS. Those who developed multiple irAEs had a trend towards improved PFS and OS compared to those who developed only a single irAE. Increased BMI but neither age nor gender were associated with irAE development. Distinct patterns of irAEs observed suggest shared etiopathogenetic mechanisms. |
| format |
article |
| author |
Melissa L. Bastacky Hong Wang Dylan Fortman Zahra Rahman Gerard P. Mascara Timothy Brenner Yana G. Najjar Yana G. Najjar Jason J. Luke Jason J. Luke John M. Kirkwood John M. Kirkwood Hassane M. Zarour Hassane M. Zarour Diwakar Davar Diwakar Davar |
| author_facet |
Melissa L. Bastacky Hong Wang Dylan Fortman Zahra Rahman Gerard P. Mascara Timothy Brenner Yana G. Najjar Yana G. Najjar Jason J. Luke Jason J. Luke John M. Kirkwood John M. Kirkwood Hassane M. Zarour Hassane M. Zarour Diwakar Davar Diwakar Davar |
| author_sort |
Melissa L. Bastacky |
| title |
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis |
| title_short |
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis |
| title_full |
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis |
| title_fullStr |
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis |
| title_full_unstemmed |
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis |
| title_sort |
immune-related adverse events in pd-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/bb1201d2dc294e4d8fa1c2c7bb33a26c |
| work_keys_str_mv |
AT melissalbastacky immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT hongwang immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT dylanfortman immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT zahrarahman immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT gerardpmascara immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT timothybrenner immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT yanagnajjar immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT yanagnajjar immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT jasonjluke immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT jasonjluke immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT johnmkirkwood immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT johnmkirkwood immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT hassanemzarour immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT hassanemzarour immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT diwakardavar immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis AT diwakardavar immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis |
| _version_ |
1718405436840869888 |